Login to Your Account



SELECTIVE ESTROGEN RECEPTOR DEGRADERS PORTFOLIO INVESTMENT

Genentech places large bet on SERDs in a potential $1.725B Seragon buy

By Marie Powers
Staff Writer

Thursday, July 3, 2014
Roche AG unit Genentech is plunking down $725 million in cash, plus contingent milestone-based payments of up to $1 billion, to purchase Seragon Pharmaceuticals Inc. and its portfolio of oral selective estrogen receptor degraders (SERDs), designed to treat hormone receptor-positive breast cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription